Holen Sie sich die Stockscreener-App
13.47
1.97%
-0.27
Handel nachbörslich:
13.47
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
KROS: ADAR1 Capital Opposes Board Re-election at Keros Therapeutics | KROS Stock News - GuruFocus
FY2025 Earnings Forecast for KROS Issued By Leerink Partnrs - MarketBeat
Q2 EPS Estimate for Keros Therapeutics Increased by Analyst - MarketBeat
HC Wainwright Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price - MarketBeat
Scotiabank Adjusts Price Target for Keros Therapeutics (KROS) | - GuruFocus
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth - Stock Titan
Keros Therapeutics (KROS) Price Target Cut to $26 by Scotiabank - GuruFocus
Levi & Korsinsky Reminds Keros Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsKROS - ACCESS Newswire
Keros Therapeutics CEO to Speak at Healthcare Conference - TipRanks
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference - The Manila Times
Voya Investment Management LLC Decreases Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (KROS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Braidwell LP - MarketBeat
William Blair Has Negative Forecast for KROS Q2 Earnings - MarketBeat
Q2 EPS Forecast for Keros Therapeutics Lowered by Analyst - MarketBeat
Leerink Partnrs Has Negative Estimate for KROS Q2 Earnings - MarketBeat
DAFNA Capital Management LLC Purchases 56,562 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect - ACCESS Newswire
Investors who lost money on Keros Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigationKROS - ACCESS Newswire
Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified - simplywall.st
Barclays PLC Boosts Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
JPMorgan Chase & Co. Acquires Significant Stake in Keros Therapeutics Inc. - GuruFocus
Alkeon Capital Management LLC Trims Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Reinforces Commitment to Maximizing Stockholder Value - The Manila Times
Keros Therapeutics Urges Stockholders to Support Board Nominees Amid ADAR1 Capital Management's Recent Communications - Nasdaq
ADAR1 Capital Management urges Keros Therapeutics for board change - Seeking Alpha
Keros Therapeutics Stockholder ADAR1 Seeks Business Restructuring Alleging Prolonged Underperformance - marketscreener.com
ADAR1 Capital Management Calls For Keros Therapeutics To Restructure Business, Reduce Headcount - marketscreener.com
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders | KROS Stock News - Stock Titan
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - marketscreener.com
Keros Therapeutics stock target cut to $25 at H.C. Wainwright By Investing.com - Investing.com India
Keros Therapeutics stock target cut to $25 at H.C. Wainwright - Investing.com
KROS Stock Target Cut by Analyst Amid Trial Setback | KROS Stock News - GuruFocus
Keros Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Wells Fargo & Company MN Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
MetLife Investment Management LLC Purchases 1,027 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics Reports Strong Q1 2025 Results - TipRanks
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Tower Research Capital LLC TRC - MarketBeat
Boxer Capital Management LLC Invests $3.96 Million in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday - Defense World
Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Keros Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
KROS Reports Strong Q1 Earnings Boosted by License Agreement | KROS Stock News - GuruFocus
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results - The Manila Times
Keros Therapeutics Swings to Massive $148M Profit as Phase 1 Trial Hits Key Goals - Stock Titan
(KROS) Long Term Investment Analysis - news.stocktradersdaily.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Emerald Mutual Fund Advisers Trust - MarketBeat
TCG Crossover Management LLC Trims Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Darwin Global Management Ltd. Grows Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Nebula Research & Development LLC Has $1.14 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
544,001 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Acquired by Lynx1 Capital Management LP - MarketBeat
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):